We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+23.65%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.28B
AUM Growth
+$464M
Cap. Flow
-$292M
Cap. Flow %
-5.53%
Top 10 Hldgs %
49.47%
Holding
185
New
37
Increased
47
Reduced
83
Closed
9

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$120M
2
FOLD
Amicus Therapeutics
FOLD
+$105M
3
NUVL
Nuvalent
NUVL
+$102M
4
KRYS icon
Krystal Biotech
KRYS
+$86.1M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$75.6M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$149M
2
INCY icon
Incyte
INCY
+$139M
3
AKRO
Akero Therapeutics
AKRO
+$113M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$109M
5
ARGX icon
argenx
ARGX
+$72.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Technology 0.1%
3 Consumer Discretionary 0.05%
4 Financials 0.03%
5 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCA icon
51
HCA Healthcare
HCA
$82.2B
$20.5M 0.39%
43,906
-21,701
-33% -$10.1M
HUM icon
52
Humana
HUM
$47.8B
$18.7M 0.35%
73,081
-3,229
-4% -$847K
VEEV icon
53
Veeva Systems
VEEV
$32.1B
$18M 0.34%
80,529
-16,977
-17% -$4.5M
PRCT icon
54
Procept Biorobotics
PRCT
$1.09B
$16.2M 0.31%
515,430
+52,026
+11% +$1.73M
NTRA icon
55
Natera
NTRA
$37.6B
$12.8M 0.24%
56,036
-35,782
-39% -$7.46M
MASI
56
DELISTED
Masimo
MASI
$12.7M 0.24%
97,285
+317
+0.3% +$45.4K
TMDX icon
57
Transmedics
TMDX
$2.54B
$11.9M 0.23%
97,885
-19,083
-16% -$2.39M
CNC icon
58
Centene
CNC
$32.5B
$11.3M 0.21%
273,674
-8,275
-3% -$310K
REGN icon
59
Regeneron Pharmaceuticals
REGN
$70.5B
$10.8M 0.2%
13,928
-1,129
-7% -$767K
PRVA icon
60
Privia Health
PRVA
$3.31B
$10.6M 0.2%
448,163
-218,014
-33% -$5.31M
TEVA icon
61
Teva Pharmaceuticals
TEVA
$36.1B
$10.2M 0.19%
327,863
-96,193
-23% -$2.37M
GPCR icon
62
Structure Therapeutics
GPCR
$3.34B
$10.1M 0.19%
145,167
-170,690
-54% -$6.97M
MRK icon
63
Merck
MRK
$307B
$9.7M 0.18%
92,117
+57,378
+165% +$5.39M
IQV icon
64
IQVIA
IQV
$34B
$9.3M 0.18%
41,267
-11,631
-22% -$2.53M
INSP icon
65
Inspire Medical Systems
INSP
$1.53B
$9.29M 0.18%
100,761
+42,113
+72% +$4.03M
CVS icon
66
CVS Health
CVS
$137B
$8.65M 0.16%
109,058
+57,859
+113% +$4.56M
CDNA icon
67
CareDx
CDNA
$1.98B
$8.12M 0.15%
431,070
-141,886
-25% -$2.38M
MOH icon
68
Molina Healthcare
MOH
$12B
$8.09M 0.15%
46,626
-44,359
-49% -$7.29M
THC icon
69
Tenet Healthcare
THC
$16.7B
$8M 0.15%
40,239
-133
-0.3% -$26.9K
WAY
70
Waystar Holding Corp
WAY
$4.24B
$7.92M 0.15%
241,734
+111,821
+86% +$3.98M
GILD icon
71
Gilead Sciences
GILD
$165B
$6.47M 0.12%
52,752
+2,859
+6% +$347K
AMGN icon
72
Amgen
AMGN
$197B
$6.05M 0.11%
18,489
+3,501
+23% +$1.11M
TXG icon
73
10x Genomics
TXG
$5.49B
$5.25M 0.1%
322,060
+8,224
+3% +$124K
ASND icon
74
Ascendis Pharma A/S
ASND
$16.5B
$5.19M 0.1%
24,330
-573
-2% -$118K
AXSM icon
75
Axsome Therapeutics
AXSM
$11.4B
$5.04M 0.1%
27,600
-24,735
-47% -$3.45M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2025 Portfolio in Review

As of Q4 2025, Bellevue Group held 185 positions worth $5.28B, up 9.6% from $4.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $292M in Q4 2025, closing 9 positions and reducing 83 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Viridian Therapeutics worth $136M.

  • Bellevue Group's largest Q4 2025 buy was Viridian Therapeutics: 4,358,527 shares worth $136M.
  • Bellevue Group added most to Krystal Biotech in Q4 2025, an estimated $86.1M increase.
  • Bellevue Group's biggest Q4 2025 reduction was Incyte, cutting an estimated $139M.
  • Bellevue Group fully exited Agios Pharmaceuticals in Q4 2025, selling an estimated $149M.
  • Bellevue Group's ten largest holdings make up 49% of its $5.28B portfolio in Q4 2025.
  • Bellevue Group opened 37 new positions and closed 9 in Q4 2025.
  • Bellevue Group's portfolio value rose 9.6% quarter-over-quarter to $5.28B.

Based on Bellevue Group's 13F filing for Q4 2025, filed 17 Feb 2026.